Vetter has successfully manufactured its first 100 clinical batches at its facility in Rankweil, Austria.
The site, which was officially opened in 2021, was built to support the manufacture and quality control of medicines for clinical trials.
In response to the recent growth in customer demand, Vetter is planning to further invest in the Ranweil site by adding a third floor to the building — creating more office space for staff.
The company is also constructing a 3400m2 technical building on site housing a technical workshop and a waste disposal centre.
According to Vetter, the construction plans will be finalised in mid-2025.
The Senior Vice President of Vetter Development Service, Dr Claus Feussner, commented: "The Rankweil facility is the European counterpart to our clinical manufacturing site in Illinois, US, and we have been proud to witness a rapid rise in customer demand since the site's opening three years ago."
Vetter's Vice President and the Site Head for Austria, Dr Martin Schwab, added: "Our success has been driven by a strong surge in project orders, which we believe will continue into the latter part of the year. We are committed to enhancing our clinical production efficiency in Rankweil — which we plan to do through increased security initiatives, technology advancements and an expansion of the workforce here in Austria."
